Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches .
Relay Therapeutics, Inc.April 16, 2021 GMT
Relay Therapeutics’ leadership in this new breed of biotech positions the company as
a strategic partner of choice for emerging technologies and founders in these fields
ZebiAI amplifies Relay Therapeutics’ Dynamo™ platform with a library of industry-leading experimental DEL data sets and validated machine learning models deployed in hit finding and optimization of novel medicines
Relay Therapeutics to host conference call at 8:00 a.m. ET
CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the acquisition of ZebiAI, a pioneer in a
Relay Therapeutics acquires startup ZebiAI for $85M - Boston Business Journal bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.